JY
CMMB

Jeff Yass’s Chemomab Therapeutics CMMB Stock Holding History

Jeff Yass’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-13,491
Closed -$21.2K – 13507
2026
Q1 		$21.2K Buy
+13,491
New +$23K ﹤0.01% 12852
2024
Q2 		– Sell
-2,869
Closed -$8.94K – 12151
2024
Q1 		$8.94K Buy
+2,869
New +$7.39K ﹤0.01% 11917

Other funds holding CMMB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $161M AUM
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Jeff Yass's CMMB Position: Q2 2026 in Review

Jeff Yass sold out of Chemomab Therapeutics (CMMB) in Q2 2026, closing a stake of 13,491 shares — an estimated $21.2K sold.

Jeff Yass first reported a position in CMMB in Q1 2024 and held it in 2 quarters. The position peaked at $21.2K in Q1 2026. 13 funds tracked by Wall St. Rank hold CMMB as of Q2 2026.

  • Jeff Yass reported no remaining Chemomab Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 13,491 Chemomab Therapeutics shares in Q2 2026, an estimated $21.2K.
  • Jeff Yass first reported a position in Chemomab Therapeutics in Q1 2024 and held it in 2 quarters.
  • Jeff Yass's Chemomab Therapeutics position peaked at $21.2K in Q1 2026.
  • 13 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.